New Zealand's controversial medicines purchasing agency Pharmac has announced that it will fund MSD's KEYTRUDA (pembrolizumab) and Roche's TECENTRIQ (atezolizumab) for people with locally advanced and metastatic non-small cell lung cancer. …
The long wait is finally over for New Zealand's lung cancer patients
March 13, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
FDA invites submissions to new rapid review priority program
July 25, 2025 - - Latest News -
Pharmac marks 12-month anniversary of funding boost
July 25, 2025 - - Latest News -
AccessCR announces finalists in Consumer Partnerships in Research Awards
July 24, 2025 - - Latest News -
Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close
July 24, 2025 - - Australian Biotech -
Australia on the list of countries to be targeted over pharmaceutical pricing
July 24, 2025 - - Latest News -
Latest trade agreements reveal US focus on resolving longstanding issues
July 24, 2025 - - Latest News -
Sanofi to acquire Vicebio, gaining rights to Queensland discovered technology
July 23, 2025 - - Australian Biotech